Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07401940 · ClinicalTrials.gov registry record · NA

HAVEN-Connect Youth Suicide Prevention

A NA study of Suicide Prevention, sponsored by George Washington University.

Recruiting
Registry status
NA
Development phase
240
Enrollment target
2
Study locations

NCT07401940: Recruiting NA study of Suicide Prevention, sponsored by George Washington University.

NCT07401940 is a NA study of Suicide Prevention that is actively recruiting participants, run by George Washington University. The registered enrollment target is 240 participants, below the 941-participant average among 21 other Suicide Prevention trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07401940, a NA study of Suicide Prevention, is actively recruiting participants, sponsored by George Washington University.

RECRUITING
Registry status
NA
Development phase
240 participants
Enrollment target
2
Study locations

Study Summary

HAVEN=CONNECT is a comprehensive depression and suicide prevention intervention that is designed to be integrated into predominantly Black churches, a strategically ideal location for mental health intervention for Black youth. HAVEN=CONNECT has three components: (1) Church Community Engagement: an interactive process of introducing the program to key church leaders and stakeholder groups. (2) Faith-Based Curriculum: educational overview for pastors, other ministerial staff and youth lay leaders on how to integrate the program into the church using communication mediums that have cultural and religious relevance in the Black Church context. (3) Youth-Connect Intervention: The goals of this project are to test the impact of HAVEN=CONNECT (HAVEN) on key intervention targets, hypothesized mediators, and build a research-informed implementation strategy for future large-scale testing.

Primary Outcome

Measures depressive symptoms and suicide risk; it asks fewer questions than traditional suicide screeners because it is response adaptive. Instead of fixing the items and allowing the precision of measurement to vary, the authors fix the precision of measurement and allow the items to vary. The K-CAT adaptively selects a small set of items from a large item-bank of 2,120 items, using a 4-point Likert scale (Strongly Agree, Agree, Disagree, Strongly Disagree). The results yield four metrics: 1) a

Conditions Studied

Interventions

  • BEHAVIORAL HAVEN-Connect
  • BEHAVIORAL HAVEN Suicide Prevention

Study Locations (2)

New York

  • Mt. Sinai Hospital; Ichon School of Medicine - New York
  • University of Rochester Medical Center - Rochester

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2023-06-01
Est. Completion 2026-05-31
Phase NA
George Washington University

133 total trials

What NCT07401940 shows while recruiting

NCT07401940 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 941-participant average among 21 other Suicide Prevention trials with a reported enrollment target (74% lower).

The record links to 1 condition, with Suicide Prevention appearing as the primary indexed condition, and to 2 interventions - of which HAVEN-Connect is the first listed.

NCT07401940 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT07401940 about?

NCT07401940 is a clinical study titled "HAVEN-Connect Youth Suicide Prevention". HAVEN=CONNECT is a comprehensive depression and suicide prevention intervention that is designed to be integrated into predominantly Black churches, a strategically ideal location for mental health intervention for Black youth. HAVEN=CONNECT has three components: (1) Church Community Engagement: an ...

What is the current status of trial NCT07401940?

This trial is currently recruiting. It is a NA study. The enrollment target is 240 participants. The study started on 2023-06-01. Estimated completion is 2026-05-31.

What conditions does trial NCT07401940 study?

This clinical trial studies the following conditions: Suicide Prevention.

What interventions are being tested in trial NCT07401940?

The interventions under investigation include: HAVEN-Connect (BEHAVIORAL), HAVEN Suicide Prevention (BEHAVIORAL).

Who is sponsoring clinical trial NCT07401940?

This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07401940 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Suicide Prevention

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07401940's enrollment target sits among peer trials

240 12th of 21 higher than 10 of 21 other Suicide Prevention trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Suicide Prevention trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02855554 · 240 participants · NA

    Quantitative Cardiac Parametric Mapping

  • NCT03230565 · 240 participants · Phase 4

    Continuous Infusions vs Scheduled Bolus Infusions

  • NCT03399929 · 240 participants

    Traumatic Brain Injury and Stroke Long Term Outcome

  • NCT03583710 · 240 participants · Phase 3

    Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07401940, the US trial registry maintained by the National Library of Medicine. NCT07401940 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.